8 stories to read for Psoriasis Action Month

August is Psoriasis Action Month, a national initiative to encourage understanding and enhance education about this common disease. According to the National Psoriasis Foundation, psoriasis affects more than 8 million Americans and roughly 125 million people worldwide.

In recognition of Psoriasis Action Month, Healio Dermatology highlights 8 recent articles on developments in research and treatment for psoriasis.

 

Patients maintain scalp psoriasis clearance with higher doses of mirikizumab

Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data presented at the World Congress of Dermatology. Read more.

 

Survey: All patients in psoriasis trials should be screened for PsA

Researchers working in clinical trials for psoriasis should standardize the use of psoriatic arthritis screening tools in all patients, according to recommendations based on an online survey and consensus meeting results organized by the International Dermatology Outcomes Measures initiative. Read more.

 

Brodalumab yields long-term skin clearance results in psoriasis

Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2. Read more.

Psoriasis on the elbow 
Psoriasis presenting on the elbow.

Ixekizumab yields ‘durable response’ in psoriasis clearance at 5 years

Patients with moderate-to-severe psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study results presented at World Congress of Dermatology in Milan. Read more.

 

Patients with severe psoriaris at risk for advance liver fibrosis

Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from King’s College London. Read more.

 

Biological agents may reduce fatigue in adults with psoriasis

Biological drugs have a small to moderate effect in reducing fatigue in patients with psoriasis vulgaris, but research is needed to understand the underlying causes in this relationship. Read more.

 

Higher BMI causally linked to greater psoriasis risk

Patients with a higher BMI have a greater risk for psoriasis, according to researchers who support healthy lifestyle initiatives for weight management in psoriasis prevention and treatment. Read more.

 

FDA approves new drug application for plaque psoriasis topical lotion

Bausch Health Companies announced that the FDA has approved its new drug application for Duobrii lotion in the topical treatment of plaque psoriasis in adults. Read More.

August is Psoriasis Action Month, a national initiative to encourage understanding and enhance education about this common disease. According to the National Psoriasis Foundation, psoriasis affects more than 8 million Americans and roughly 125 million people worldwide.

In recognition of Psoriasis Action Month, Healio Dermatology highlights 8 recent articles on developments in research and treatment for psoriasis.

 

Patients maintain scalp psoriasis clearance with higher doses of mirikizumab

Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data presented at the World Congress of Dermatology. Read more.

 

Survey: All patients in psoriasis trials should be screened for PsA

Researchers working in clinical trials for psoriasis should standardize the use of psoriatic arthritis screening tools in all patients, according to recommendations based on an online survey and consensus meeting results organized by the International Dermatology Outcomes Measures initiative. Read more.

 

Brodalumab yields long-term skin clearance results in psoriasis

Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2. Read more.

Psoriasis on the elbow 
Psoriasis presenting on the elbow.

Ixekizumab yields ‘durable response’ in psoriasis clearance at 5 years

Patients with moderate-to-severe psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study results presented at World Congress of Dermatology in Milan. Read more.

 

Patients with severe psoriaris at risk for advance liver fibrosis

Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from King’s College London. Read more.

 

Biological agents may reduce fatigue in adults with psoriasis

Biological drugs have a small to moderate effect in reducing fatigue in patients with psoriasis vulgaris, but research is needed to understand the underlying causes in this relationship. Read more.

 

Higher BMI causally linked to greater psoriasis risk

Patients with a higher BMI have a greater risk for psoriasis, according to researchers who support healthy lifestyle initiatives for weight management in psoriasis prevention and treatment. Read more.

 

FDA approves new drug application for plaque psoriasis topical lotion

Bausch Health Companies announced that the FDA has approved its new drug application for Duobrii lotion in the topical treatment of plaque psoriasis in adults. Read More.